top of page
Browse by category
Search


SURMOUNT-5: Tirzepatide shows superior weight loss over semaglutide
Seventy-two week outcomes from the SURMOUNT-5 clinical trial have shown that tirzepatide (Zepbound) met the primary endpoint and all five...


SURMOUNT-5: Zepbound superior to Wegovy in head-to-head trial showing an average weight loss of 20.2% vs. 13.7%
Eli Lilly and Company has announced topline results from the SURMOUNT-5 phase 3b open-label randomised clinical trial that found Zepbound...


SURMOUNT-5: Tirzepatide and semaglutide go head-to-head in battle of weight loss drugs
Eli Lilly and Company has registered its intent to carry out a Phase 3b clinical trial that will see the company’s tirzepatide (Mounjaro)...
Browse by tag






bottom of page